JP3802721B2 - Biological collagen synthesis promoter - Google Patents
Biological collagen synthesis promoter Download PDFInfo
- Publication number
- JP3802721B2 JP3802721B2 JP31546199A JP31546199A JP3802721B2 JP 3802721 B2 JP3802721 B2 JP 3802721B2 JP 31546199 A JP31546199 A JP 31546199A JP 31546199 A JP31546199 A JP 31546199A JP 3802721 B2 JP3802721 B2 JP 3802721B2
- Authority
- JP
- Japan
- Prior art keywords
- collagen
- gly
- gelatin
- amino acid
- hyp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は生体内でのコラーゲン合成の促進活性を高める剤に関する。
【0002】
【従来の技術】
コラーゲンは生体内のタンパク質の約1/3を占めるタンパク質で、血管や皮膚、骨に多く存在する。コラーゲンは消化酵素でほとんど分解されないため栄養価の低いタンパク質と考えられたことがあったが、コラーゲンを摂取することによる新陳代謝促進(特開平7−278012)、頭髪の直径が太くなる(Nutrition Reports International,13,579,1976)ことや、関節症治療用薬剤としての利用(特開昭63−39821)が報告され、有用性が見直されている。更にこのコラーゲンタンパクは加齢とともに減少することから血管の脆弱化や皮膚の弾力性・柔軟性の減少などの一因と考えられている。近年、コラーゲンタンパクもしくはその加水分解物の経口摂取による皮膚の新陳代謝促進に関する特許(特開平7−278012)も開示され、主に美容向けの健康食品が多数販売されている。
【0003】
コラーゲンの熱変性体であるゼラチンは、その高い粘性、凝固性、保水性および保湿性を利用して、食品の食感改良剤や化粧品(特開昭52−111600)として使用されている。しかし、未処理のコラーゲンおよびゼラチンは粘性が高く凝固し易い性質を持つため、部分加水分解処理されたものを使用することが多い。また、タンパク質であるため抗原性を有し、アレルギー体質のヒトの摂取には問題がある。そのため、コラーゲンをコラゲナーゼによって、低分子化することにより抗原性をなくしアレルギー患者向けのタンパク質源あるいは輸液製剤成分としての利用が開示されている(特開平7−82299)。
【0004】
コラゲナーゼによるコラーゲンの分解物の生理活性については、フィブリン凝集阻害活性(特開平6−46875)、麻酔作用(Br.J.Pharmacol.,69,551,1980)が知られている。また、Clostridium histolyticum由来のコラゲナーゼによるコラーゲンの分解産物に関しては、Nagai,Y.が、生成するトリペプタイドの36%がGly−Pro−Hypでもっとも多いと報告している(J.Biochem.,50,486,1961)。
【0005】
コラーゲンタンパクもしくはその加水分解物の経口摂取により生体のコラーゲンタンパク生合成を促進させ、生体コラーゲンの新陳代謝を高める場合、0.5〜40gの摂取が必要とされており(特開平7−278012)、イタリアにおいては1日あたり2〜6gの摂取を推奨している。しかしながら、数gのコラーゲンタンパク摂取は、臭いや凝固性の点から通常の食品に添加することは現実的でない。
【0006】
【発明が解決しようとする課題】
本発明の目的は、生体内コラーゲンタンパク合成活性を飛躍的に高めることができる生体コラーゲン合成促進剤を提供することである。
【0007】
【課題を解決するための手段】
本発明者らは、前記のような問題点を解決するためにコラーゲンタンパクの経口摂取の薬理作用について鋭意研究を重ねた結果、コラーゲンタンパクを特定の分子量以下まで加水分解することにより、上記目的を達成できることを見出し、本発明に到達した。
即ち、本発明は、コラーゲンまたはゼラチンの分解物であって分子量が400以下のものを含有することを特徴とする生体コラーゲン合成促進剤である。コラーゲンまたはゼラチンの分解物としては、アミノ酸配列がGly−X−Y(X,Yはアミノ酸)であるペプタイドが好ましく、特に好ましくはアミノ酸配列がGly−Pro−Hypのものである。
また、本発明はアミノ酸配列がGly−X−Y(X,Yはアミノ酸)であるペプタイドを含有することを特徴とする生体コラーゲン合成促進剤であり、好ましくはアミノ酸配列がGly−Pro−Hypのものである。
【0008】
【発明の実施の形態】
本発明に用いられるコラーゲンタンパクは、例えば牛や豚などの動物の皮膚、骨および腱などの結合組織から抽出したもの、もしくはコラーゲンタンパクの熱変性物であるゼラチンがある。
【0009】
本発明におけるコラーゲンまたはゼラチンの分解物とは分子量が400以下のものである。コラーゲン又はゼラチンの加水分解は加水分解酵素による方法でもよく、酸あるいはアルカリによる加水分解であっても問題ない。酵素分解に用いる加水分解酵素としては、例えばコラゲナーゼ酵素においては、Clostridium histoticum,Streptomyces parvulusなどの細菌、放線菌あるいは真菌など由来のものを使用できる。また遺伝子組み替え技術により他の菌体に産生させたもので、類似の基質特異性を有する酵素であっても問題はなく、これらの微生物により発酵させることも有効である。さらに、その他のタンパク質加水分解酵素の混合物であってもよい。好ましくはGly−X−Y(X,Yはアミノ酸)であらわされるペプタイドを生成するものである。
【0010】
分子量が400以下のコラーゲンまたはゼラチンの分解物は精製したものでもよいが、精製しなくても差し支えない。例えば他のコラーゲンまたはゼラチンの分解生成物等の混合物でもよい。
【0011】
コラーゲンの加水分解物は、既に市販されている。これらの酵素的に加水分解されたコラーゲンの多くは、分子量の分布範囲が二千から八万である。これらの加水分解物は水に対する分散性の向上を目的とするものであって、生体内でのコラーゲン合成促進活性の向上を目的としたものではない。これに対して本発明のコラーゲン加水分解物は、特定の有効成分として分子量で約400以下のペプタイドを含むことを特徴とし、その加水分解処理により、生体内でのコラーゲン合成促進活性を飛躍的に向上させることができる。
【0012】
本発明におけるコラーゲンまたはゼラチンの分解物は、好ましくは、アミノ酸配列がGly−X−Yのペプタイドであり、特に好ましくはアミノ酸配列がGly−Pro−Hypのものである。
また、アミノ酸配列がGly−X−Yのペプタイドの場合は、コラーゲンまたはゼラチンの分解物でなくとも差し支えなく、液相法、固相法に代表されるペプタイドの化学合成法により合成されたペプタイドであっても問題ない。好ましくは、アミノ酸配列がGly−Pro−Hypのものである。
【0013】
分子量が400以下のコラーゲンまたはゼラチンの分解物またはアミノ酸配列がGly−X−Yのペプタイドの量は全剤中1質量%以上が好ましく、特に好ましくは15質量%以上である。分解物はゲルろ過などにより、分子量400以下のペプタイド部分を高度に精製することもできる。
本発明の生体コラーゲン合成促進剤は、経口摂取可能な形態、例えば粉末、散剤、顆粒、錠剤、カプセルなどの剤型にすることができ、また飲料などの食品に配合することもできる。摂取量は特に制限はないが、通常分子量が400以下のコラーゲンまたはゼラチンの分解物またはアミノ酸配列がGly−X−Yのペプタイドの量が0.03〜3g/日となるような量である。さらに外用剤として軟膏や化粧品に配合しても問題ない。
【0014】
【実施例】
以下に実施例を挙げて本発明を詳細に説明するが、本発明はこれらに限定されるものではない。
【0015】
調製例1
コラーゲンタンパクとして、ウシ真皮より調製したゼラチン30gを蒸留水300mlに加温溶解し、0.45μmのフィルターで滅菌ろ過した。
【0016】
調製例2
コラーゲンタンパクとして、ウシ真皮より調製したゼラチン30gを蒸留水300mlに加温溶解した。コラゲナーゼタイプI(Worthington Biochemical Corp.)300mgを加え、アンモニア水にてpHを7.5に調整した後37℃で1時間放置した。反応終了後、反応液を100℃で3分間加熱しコラゲナーゼを失活させ、次いで0.45μmのフィルターで滅菌ろ過した。このろ液をCDP−0とする。
このろ液CDP−0を蒸留水で平衡化したSephadex LH-20(Pharmacia)によるゲルろ過を行い2つの画分(CDP−1,CDP−2)に分け、それぞれを凍結乾燥した。ゲルろ過のクロマトを図1に示す。それぞれのピークをSuperdex Peptide HR10/30(Pharmacia)を用いて、0.3M NaClを含む0.1Mリン酸ナトリウム緩衝溶液(pH7.2)を溶出液に用いて分子量を求めたところ、CDP−1が約12000〜500に分布し、CDP−2が約350だった。CDP−2の約50%がGly−Pro−Hypであった。
【0017】
調製例3
コラーゲンタンパクとして、ウシ真皮より調製したゼラチン30gを蒸留水300mlに加温溶解した。ペプシン(Biozyme Lab.,LTD.)300mgを加え、希塩酸にてpHを2.0に調整した後37℃で1時間放置した。反応終了後、水酸化ナトリウム水溶液でpHを7に調整した後100℃で3分間加熱しペプシンを失活させ、次いで0.45μmのフィルターで滅菌ろ過した。このものの分子量を測定したところ、12000付近をピークに20000〜60に広く分布していた。図2にLH-20によるゲルろ過のクロマトを示す。
【0018】
調製例4
表−1に示すアミノ酸組成物を蒸留水300mlに溶解し、0.45μmのフィルターで滅菌ろ過した。この組成はコラーゲンを構成するアミノ酸の組成に等しい。
【0019】
【表1】
【0020】
調製例5
tert.BOCアミノ酸誘導体を用いる液相法により、Gly−Pro−Hypを合成した。合成品は6N塩酸中、110℃で22時間加水分解し、アミノ酸分析を行った。アミノ酸分析値と元素分析値を以下に示す。
アミノ酸分析:Gly 1.00(1),Pro 1.05(1),Hyp 1.05(1)、元素分析:C 43.22(43.11),H 6.43(6.45),N 12.37(12.57) C12H19N3O5・HCl・0.7H2Oとして、括弧内は理論値。
【0021】
実施例1
6週齢のWistar系雄性ラット(日本クレア(株))を1週間予備飼育した後、1〜5の5群、一群5匹に分けた。ラットの飼育は温度23℃、湿度55%環境下で行い、飼料はCE−2(日本クレア(株))を用い、飲料水とともに自由摂取させた。各群にはクエン酸でpHを3.8〜4.0に調整した試料液を1日1回、13日間連続で胃ゾンデを用いて投与した。ペントバルビタール麻酔下、右腹側部を採取し可溶性コラーゲン量をハドロキシプロリン(Hyp)を指標に測定した。結果を表−2に示す。
CDP−2が含まれているCDP−0を与えた群3は、蒸留水を与えた群1に比較して可溶性コラーゲン量の量が著しく多かった。これに対してゼラチン自体である調製例1とペプシンで分解し分子量が大きい調製例3の物質を与えた群2,4は可溶性コラーゲン量の増加量が少なく、アミノ酸の混合物である調製例4を与えた群5は群1とほとんど変わらなかった。
【0022】
【表2】
【0023】
実施例2
TIG103ヒト皮膚正常細胞(財団法人ヒューマンサイエンス振興財団)を10%の非動化したウシ胎児血清を含むEMEM中37℃、5%炭酸ガス雰囲気下で培養した。コンフルエントになった後、血清濃度を0.5%に下げ24時間培養し、100μg/mlのアスコルビン酸とCDP−1あるいはCDP−2を添加しさらに12時間培養した。細胞を生理食塩水で洗浄した後RNAをIsogenTM(ニッポンジーン)を用いて抽出し、32Pで標識したヒトタイプIコラーゲンおよびβアクチンのcDNAプローブにてノーザンブロットを行った。結果を表−3に示す。
アスコルビン酸とCDP−2および合成ペプチド(Gly−Pro−Hyp)の併用群にのみコラーゲン遺伝子の増加が見られる。活性ペプチドは分子量で約400以下ペプチドであり、その活性本体のひとつとしてGly−Pro−Hypであることがわかる。
【0024】
【表3】
【0025】
【発明の効果】
以上から明らかなように、分子量400以下のコラーゲン又はゼラチン分解物又はアミノ酸配列がGly−X−Y(X,Yはアミノ酸)トリペプチド、特にGly−Pro−Hypは、生体コラーゲンの合成促進剤として極めて有効である。
【図面の簡単な説明】
【図1】図1はコラゲナーゼで分解したゼラチンのLH−20のクロマトグラフである。先に溶出される大きな分子量画分をCDP−1とし、後の小さな分子量画分をCDP−2とした。
【図2】図2はペプシンで分解したゼラチンのLH−20のクロマトグラフである。全体をひとつの画分とした。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to an agent that enhances the activity of promoting collagen synthesis in vivo.
[0002]
[Prior art]
Collagen is a protein that occupies about one third of the protein in the body, and is present in a large amount in blood vessels, skin, and bones. Collagen was considered to be a protein with low nutritional value because it is hardly degraded by digestive enzymes, but it promoted metabolism by ingesting collagen (Japanese Patent Laid-Open No. 7-278012), and the hair diameter became thick (Nutrition Reports International , 13, 579, 1976) and utilization as a drug for treating arthropathy (Japanese Patent Laid-Open No. 63-39821) has been reported and its usefulness has been reviewed. Furthermore, since this collagen protein decreases with aging, it is considered to be one of the causes such as weakening of blood vessels and reduction of skin elasticity and flexibility. In recent years, a patent (Japanese Patent Laid-Open No. 7-278012) relating to promotion of skin metabolism by oral intake of collagen protein or a hydrolyzate thereof has also been disclosed, and many health foods mainly for beauty are sold.
[0003]
Gelatin, which is a heat-denatured product of collagen, is used as a food texture improving agent and cosmetics (Japanese Patent Laid-Open No. 52-111600) by utilizing its high viscosity, coagulation, water retention and moisture retention. However, untreated collagen and gelatin are highly viscous and easily coagulate, so that those that have been partially hydrolyzed are often used. Moreover, since it is a protein, it has antigenicity, and there is a problem in the intake of humans who are allergic. For this reason, the use of collagen as a protein source or an infusion preparation component for allergic patients by reducing the molecular weight of collagen with collagenase has been disclosed (JP-A-7-82299).
[0004]
Regarding the physiological activity of collagen degradation products by collagenase, fibrin aggregation inhibitory activity (JP-A-6-46875) and anesthetic action (Br. J. Pharmacol., 69, 551, 1980) are known. As for collagen degradation products by collagenase derived from Clostridium histolyticum, Nagai, Y. reports that 36% of the tripeptide produced is the most in Gly-Pro-Hyp (J. Biochem., 50, 486, 1961).
[0005]
In order to promote the biosynthesis of collagen protein in the living body by ingesting collagen protein or a hydrolyzate thereof and increase the metabolism of living collagen, the intake of 0.5 to 40 g is required (JP-A-7-278012), In Italy, it is recommended to take 2-6g per day. However, it is not practical to add several grams of collagen protein to ordinary foods in terms of odor and coagulability.
[0006]
[Problems to be solved by the invention]
An object of the present invention is to provide a biological collagen synthesis promoter that can dramatically increase in vivo collagen protein synthesis activity.
[0007]
[Means for Solving the Problems]
As a result of intensive studies on the pharmacological action of collagen protein ingestion in order to solve the above problems, the present inventors have achieved the above object by hydrolyzing collagen protein to a specific molecular weight or less. We have found that this can be achieved and have reached the present invention.
That is, the present invention is a biological collagen synthesis promoter characterized by containing a degradation product of collagen or gelatin and having a molecular weight of 400 or less. As a degradation product of collagen or gelatin, a peptide having an amino acid sequence of Gly-XY (X and Y are amino acids) is preferable, and an amino acid sequence of Gly-Pro-Hyp is particularly preferable.
Further, the present invention is a biological collagen synthesis promoter characterized by containing a peptide whose amino acid sequence is Gly-XY (where X and Y are amino acids), preferably the amino acid sequence is Gly-Pro-Hyp. Is.
[0008]
DETAILED DESCRIPTION OF THE INVENTION
Examples of the collagen protein used in the present invention include those extracted from the skin of animals such as cows and pigs, connective tissues such as bones and tendons, and gelatin that is a heat-denatured collagen protein.
[0009]
The degradation product of collagen or gelatin in the present invention has a molecular weight of 400 or less. Collagen or gelatin may be hydrolyzed by a hydrolase method, or by acid or alkali. As the hydrolase used for the enzymatic degradation, for example, collagenase enzyme may be derived from bacteria such as Clostridium histoticum, Streptomyces parvulus, actinomycetes or fungi. Moreover, it is produced in another microbial cell by gene recombination technology, and there is no problem even if the enzyme has a similar substrate specificity. Fermentation with these microorganisms is also effective. Furthermore, it may be a mixture of other proteolytic enzymes. Preferably, it produces a peptide represented by Gly-XY (where X and Y are amino acids).
[0010]
A degradation product of collagen or gelatin having a molecular weight of 400 or less may be purified, but may not be purified. For example, it may be a mixture of other collagen or gelatin degradation products.
[0011]
Collagen hydrolysates are already commercially available. Many of these enzymatically hydrolyzed collagens have a molecular weight distribution range of 2000 to 80,000. These hydrolysates are intended to improve water dispersibility and are not intended to improve collagen synthesis promoting activity in vivo. On the other hand, the collagen hydrolyzate of the present invention is characterized by containing a peptide having a molecular weight of about 400 or less as a specific active ingredient, and the hydrolysis treatment dramatically improves the activity of promoting collagen synthesis in vivo. Can be improved.
[0012]
The degradation product of collagen or gelatin in the present invention is preferably a peptide having an amino acid sequence of Gly-XY, and particularly preferably an amino acid sequence of Gly-Pro-Hyp.
In the case of a peptide having an amino acid sequence of Gly-X-Y, it may not be a degradation product of collagen or gelatin, and may be a peptide synthesized by a chemical synthesis method of a peptide represented by a liquid phase method or a solid phase method. There is no problem even if it exists. Preferably, the amino acid sequence is that of Gly-Pro-Hyp.
[0013]
The amount of a collagen or gelatin degradation product having a molecular weight of 400 or less or a peptide having an amino acid sequence of Gly-XY is preferably 1% by mass or more, particularly preferably 15% by mass or more, based on the total amount. The degradation product can also highly purify a peptide portion having a molecular weight of 400 or less by gel filtration or the like.
The biocollagen synthesis promoter of the present invention can be in a form that can be taken orally, for example, powder, powder, granule, tablet, capsule and the like, and can also be incorporated into foods such as beverages. The amount of intake is not particularly limited, but is usually such that the amount of collagen or gelatin degradation product having a molecular weight of 400 or less or a peptide having an amino acid sequence of Gly-XY is 0.03 to 3 g / day. Furthermore, there is no problem even if it is blended into an ointment or cosmetic as an external preparation.
[0014]
【Example】
Hereinafter, the present invention will be described in detail with reference to examples, but the present invention is not limited thereto.
[0015]
Preparation Example 1
As collagen protein, 30 g of gelatin prepared from bovine dermis was heated and dissolved in 300 ml of distilled water, and sterilized by filtration with a 0.45 μm filter.
[0016]
Preparation Example 2
As collagen protein, 30 g of gelatin prepared from bovine dermis was dissolved by heating in 300 ml of distilled water. Collagenase type I (Worthington Biochemical Corp.) 300 mg was added, the pH was adjusted to 7.5 with aqueous ammonia, and the mixture was allowed to stand at 37 ° C. for 1 hour. After completion of the reaction, the reaction solution was heated at 100 ° C. for 3 minutes to inactivate collagenase, and then sterilized by filtration with a 0.45 μm filter. This filtrate is designated as CDP-0.
This filtrate CDP-0 was subjected to gel filtration with Sephadex LH-20 (Pharmacia) equilibrated with distilled water to divide it into two fractions (CDP-1, CDP-2), and each was freeze-dried. The chromatographic gel filtration is shown in FIG. When the molecular weight of each peak was determined using Superdex Peptide HR10 / 30 (Pharmacia) and 0.1M sodium phosphate buffer solution (pH 7.2) containing 0.3M NaCl as eluent, CDP-1 Distributed about 12000-500 and CDP-2 was about 350. About 50% of CDP-2 was Gly-Pro-Hyp.
[0017]
Preparation Example 3
As collagen protein, 30 g of gelatin prepared from bovine dermis was dissolved by heating in 300 ml of distilled water. 300 mg of pepsin (Biozyme Lab., LTD.) Was added, the pH was adjusted to 2.0 with dilute hydrochloric acid, and the mixture was allowed to stand at 37 ° C. for 1 hour. After completion of the reaction, the pH was adjusted to 7 with an aqueous sodium hydroxide solution, heated at 100 ° C. for 3 minutes to inactivate pepsin, and then sterile filtered through a 0.45 μm filter. When the molecular weight of this product was measured, it was widely distributed from 20000 to 60 with a peak around 12000. Fig. 2 shows the gel filtration chromatography using LH-20.
[0018]
Preparation Example 4
The amino acid composition shown in Table 1 was dissolved in 300 ml of distilled water and sterilized by filtration with a 0.45 μm filter. This composition is equal to the composition of amino acids constituting collagen.
[0019]
[Table 1]
[0020]
Preparation Example 5
Gly-Pro-Hyp was synthesized by a liquid phase method using a tert.BOC amino acid derivative. The synthesized product was hydrolyzed in 6N hydrochloric acid at 110 ° C. for 22 hours and subjected to amino acid analysis. Amino acid analysis values and elemental analysis values are shown below.
Amino acid analysis: Gly 1.00 (1), Pro 1.05 (1), Hyp 1.05 (1), Elemental analysis: C 43.22 (43.11), H 6.43 (6.45), N 12.37 (12.57) C 12 H 19 N 3 O 5 The value in parentheses is the theoretical value as HCl · 0.7H 2 O.
[0021]
Example 1
Six-week-old Wistar male rats (CLEA Japan, Inc.) were preliminarily raised for 1 week, and then divided into 5 groups of 1 to 5 and 5 animals per group. Rats were reared at a temperature of 23 ° C. and a humidity of 55%, and CE-2 (Nippon Claire Co., Ltd.) was used as a feed, which was freely ingested with drinking water. Each group was administered with a sample solution whose pH was adjusted to 3.8 to 4.0 with citric acid once a day for 13 consecutive days using a stomach tube. Under pentobarbital anesthesia, the right ventral region was collected, and the amount of soluble collagen was measured using hadroxyproline (Hyp) as an index. The results are shown in Table-2.
Group 3 to which CDP-0 containing CDP-2 was given had significantly more soluble collagen than
[0022]
[Table 2]
[0023]
Example 2
TIG103 human skin normal cells (Human Science Promotion Foundation) were cultured in EMEM containing 10% non-immobilized fetal calf serum at 37 ° C. in a 5% carbon dioxide atmosphere. After becoming confluent, the serum concentration was lowered to 0.5% and cultured for 24 hours, and 100 μg / ml ascorbic acid and CDP-1 or CDP-2 were added and further cultured for 12 hours. After washing the cells with physiological saline, RNA was extracted using Isogen ™ (Nippon Gene), and Northern blotting was performed with 32 P-labeled human type I collagen and β-actin cDNA probes. The results are shown in Table-3.
Only in the combination group of ascorbic acid, CDP-2 and synthetic peptide (Gly-Pro-Hyp), an increase in the collagen gene is observed. The active peptide is a peptide having a molecular weight of about 400 or less, and Gly-Pro-Hyp is one of the active bodies.
[0024]
[Table 3]
[0025]
【The invention's effect】
As is clear from the above, collagen having a molecular weight of 400 or less or a gelatin degradation product, or a tripeptide having an amino acid sequence of Gly-XY (where X and Y are amino acids), particularly Gly-Pro-Hyp, is used as a biosynthesis promoter. It is extremely effective.
[Brief description of the drawings]
FIG. 1 is a chromatograph of LH-20 of gelatin degraded with collagenase. The large molecular weight fraction eluted first was CDP-1, and the later small molecular weight fraction was CDP-2.
FIG. 2 is a chromatograph of LH-20 of gelatin degraded with pepsin. The whole was made into one fraction.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP31546199A JP3802721B2 (en) | 1999-11-05 | 1999-11-05 | Biological collagen synthesis promoter |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP31546199A JP3802721B2 (en) | 1999-11-05 | 1999-11-05 | Biological collagen synthesis promoter |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005314259A Division JP2006056904A (en) | 2005-10-28 | 2005-10-28 | Accelerator for synthesizing biogenic collagen |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001131084A JP2001131084A (en) | 2001-05-15 |
JP3802721B2 true JP3802721B2 (en) | 2006-07-26 |
Family
ID=18065647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP31546199A Expired - Lifetime JP3802721B2 (en) | 1999-11-05 | 1999-11-05 | Biological collagen synthesis promoter |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3802721B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4433082B1 (en) * | 2008-10-31 | 2010-03-17 | ユーハ味覚糖株式会社 | Neurogenesis promoter |
JP2010104364A (en) * | 2009-09-18 | 2010-05-13 | Uha Mikakuto Co Ltd | Food and drink containing neurogenesis promoter |
JP2014062048A (en) * | 2012-09-19 | 2014-04-10 | Sanyo Chem Ind Ltd | Collagen production promoter, culture medium for promoting collagen production, anti-aging agent, gel for promoting collagen production, and method of producing gel for promoting collagen production |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4033877B2 (en) | 2005-09-29 | 2008-01-16 | 株式会社ファンケル | Composition for promoting type I collagen production |
JP5016830B2 (en) * | 2006-03-17 | 2012-09-05 | ゼライス株式会社 | Method for producing purified peptide |
WO2007111238A1 (en) | 2006-03-23 | 2007-10-04 | Kyowa Hakko Kogyo Co., Ltd. | Oral agent for promoting synthesis of tissue collagen |
US20100068342A1 (en) | 2006-11-15 | 2010-03-18 | Meji Seika Kaisha Ltd | Collagen peptide composition and food or beverage containing the same |
JP5632162B2 (en) * | 2007-06-01 | 2014-11-26 | 協和発酵バイオ株式会社 | Oral composition |
JP4995155B2 (en) * | 2008-07-23 | 2012-08-08 | 株式会社ディーエイチシー | Biocollagen synthesis promoter, and cosmetic and quasi-drugs for biosynthesis synthesis promotion |
JP5890175B2 (en) | 2009-04-28 | 2016-03-22 | 株式会社明治 | Collagen peptide composition having high blood transferability and food and drink containing the same |
CN101779733B (en) * | 2010-03-29 | 2012-12-26 | 济南环亿生物科技有限公司 | Feed additive for improving collagen in livestock and poultry muscle and production method thereof and application thereof |
JP2012062278A (en) * | 2010-09-16 | 2012-03-29 | Fancl Corp | Cosmetic beverage containing apple extract and collagen tripeptide |
JP6517546B2 (en) * | 2015-03-11 | 2019-05-22 | 株式会社ファンケル | Fibroblast cell proliferation promoter |
CN118159651A (en) * | 2021-09-28 | 2024-06-07 | 天野酶制品株式会社 | Enzyme agent for producing collagen tripeptide or decomposing cartilage |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06199626A (en) * | 1992-12-28 | 1994-07-19 | Yamakawa Boeki Kk | Additive for preparing beauty product containing new oligopeptide |
JP3146251B2 (en) * | 1993-09-10 | 2001-03-12 | 宮城化学工業株式会社 | Peptide composition and method for producing the same |
JP3782122B2 (en) * | 1994-04-11 | 2006-06-07 | サンスター株式会社 | Metabolism promoter for oral intake and food containing the same |
JP4609807B2 (en) * | 1996-03-28 | 2011-01-12 | 雪印乳業株式会社 | Bone-strengthening medicine, food and drink, and feed |
-
1999
- 1999-11-05 JP JP31546199A patent/JP3802721B2/en not_active Expired - Lifetime
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4433082B1 (en) * | 2008-10-31 | 2010-03-17 | ユーハ味覚糖株式会社 | Neurogenesis promoter |
JP2010105996A (en) * | 2008-10-31 | 2010-05-13 | Uha Mikakuto Co Ltd | Neurogenesis promoter |
JP2010104364A (en) * | 2009-09-18 | 2010-05-13 | Uha Mikakuto Co Ltd | Food and drink containing neurogenesis promoter |
JP2014062048A (en) * | 2012-09-19 | 2014-04-10 | Sanyo Chem Ind Ltd | Collagen production promoter, culture medium for promoting collagen production, anti-aging agent, gel for promoting collagen production, and method of producing gel for promoting collagen production |
Also Published As
Publication number | Publication date |
---|---|
JP2001131084A (en) | 2001-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4947475B2 (en) | Hydrolyzate of avian cartilage and its preparation method and use | |
JP3802721B2 (en) | Biological collagen synthesis promoter | |
Zhao et al. | Antihypertensive effect and purification of an ACE inhibitory peptide from sea cucumber gelatin hydrolysate | |
EP2330112B1 (en) | Collagen peptide, dipeptide, and agent for prevention of disease | |
CN101289507B (en) | Collagen protein and collagen polypeptides, preparation thereof and applications | |
JP5653759B2 (en) | Skin aging inhibitory peptide | |
JP2002255847A (en) | Collagen production promoter, functional food and pharmaceutical preparation | |
KR100894528B1 (en) | Skin care agent | |
JP2805194B2 (en) | Peptide for increasing blood triglyceride concentration and blood triglyceride concentration increase inhibitor containing the peptide as an active ingredient | |
US5466669A (en) | Immunostimulatory agent | |
JP2006056904A (en) | Accelerator for synthesizing biogenic collagen | |
WO2007131424A1 (en) | Method for preparing low molecular weight proteoglycan and collagen compositions, its products and uses | |
CN114106092B (en) | Active polypeptide with ACE inhibition effect and application thereof | |
KR101789355B1 (en) | Skin collagen production-promoting agent | |
JP5778692B2 (en) | Disease inhibitor | |
JP6153469B2 (en) | Composition containing hydrolyzate of soy protein | |
JP2009120512A (en) | Joint cartilage regeneration promoter | |
JP4698935B2 (en) | Skin collagen production promoter | |
JP2737790B2 (en) | Food containing silk protein hydrolyzate and method for producing the same | |
KR20060037245A (en) | Skin collagen production promoter | |
JP2800877B2 (en) | Peptide for increasing blood triglyceride concentration and blood triglyceride concentration increase inhibitor containing the peptide as an active ingredient | |
US20150202311A1 (en) | Collagen-peptide complex | |
Costa et al. | Effect of intraperitoneally administered hydrolyzed whey protein on blood pressure and renal sodium handling in awake spontaneously hypertensive rats | |
JP4295387B2 (en) | Method for producing degradable peptides | |
JP2004244369A (en) | Peptide composition, method for producing the same and peptide-added material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050830 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051028 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20051028 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060411 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060428 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 3802721 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090512 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090512 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100512 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100512 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110512 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120512 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120512 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130512 Year of fee payment: 7 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130512 Year of fee payment: 7 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |